| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
Nicotinic acid N-oxide does not have a well-defined target. It is a nicotinic acid derivative used to treat hyperlipidemia. It may act through similar mechanisms as nicotinic acid, but its specific target is not clearly established.
|
|---|---|
| ln Vitro |
In cell-free systems, the activity of Nicotinic acid N-oxide is not typically studied. It is a small molecule with known chemical properties. Its ability to form hydrogen bonds may be relevant to its interactions with other molecules. Nicotinic acid N-oxide has been reported to inhibit the Menin-MLL interaction in MLL-related leukemias and block Ebola virus entry, with AC50 values ranging from 5.012 µM to 31622.8 nM. This suggests diverse bioactivities beyond its lipid-lowering effects.
|
| ln Vivo |
In vivo, Nicotinic acid N-oxide is used to treat hyperlipidemia. Its efficacy in lowering lipid levels is established. Its other potential activities, such as antiviral effects, require further in vivo validation.
|
| Enzyme Assay |
In vitro assays for Nicotinic acid N-oxide are not standard. Its lipid-lowering activity may be assessed in cell-based assays measuring lipid accumulation. Its Menin-MLL interaction inhibition is measured in biochemical assays.
|
| Cell Assay |
Cell-based assays are used to study its effects on lipid metabolism or viral entry. For example, its ability to inhibit Ebola virus entry is assessed in cell culture models using pseudotyped viruses. Its effects on leukemic cells are studied in vitro.
|
| Animal Protocol |
In vivo studies are conducted in animal models of hyperlipidemia. The compound is administered, and its effects on serum lipid levels are measured. Its antiviral activity may be evaluated in animal models of Ebola or other viral infections.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Nicotinic acid N-oxide are not well-documented. As a derivative of nicotinic acid, it may share some of its pharmacokinetic characteristics, such as oral bioavailability and hepatic metabolism. Further studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for Nicotinic acid N-oxide is limited. Side effects may be similar to those of nicotinic acid, such as flushing and gastrointestinal disturbances. Its safety profile requires further investigation.
|
| Additional Infomation |
Oxiniacic acid is an aromatic carboxylic acid belonging to the pyridine class of compounds. It is a derivative of nicotinic acid.
Nicotinic acid N-oxide is a nicotinic acid derivative used to treat hyperlipidemia. It has been investigated for other activities, including antiviral effects. It is a research compound and may have therapeutic applications. |
| Molecular Formula |
C6H5NO3
|
|---|---|
| Molecular Weight |
139.1088
|
| Exact Mass |
139.026
|
| CAS # |
2398-81-4
|
| PubChem CID |
16976
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
469.0±18.0 °C at 760 mmHg
|
| Melting Point |
254-255 °C (dec.)(lit.)
|
| Flash Point |
237.4±21.2 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
-1.52
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
137
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FJCFFCXMEXZEIM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H5NO3/c8-6(9)5-2-1-3-7(10)4-5/h1-4H,(H,8,9)
|
| Chemical Name |
1-oxidopyridin-1-ium-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~89.86 mM)
H2O : ~0.1 mg/mL (~0.72 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1886 mL | 35.9428 mL | 71.8856 mL | |
| 5 mM | 1.4377 mL | 7.1886 mL | 14.3771 mL | |
| 10 mM | 0.7189 mL | 3.5943 mL | 7.1886 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
